The FreeStyle Libre 2 reader typically costs between $130 and $150 without insurance coverage.
A month's supply of two sensors for the FreeStyle Libre 2 system costs around $139, leading to an annual cost of approximately $1,560.
Also worth reading: What are the most common AI insurance policy exclusions and how can businesses avoid coverage gaps? · Is e-bike insurance required like car insurance in 2026, and how do the coverage differences compare? · How do I optimize insurance coverage for AI operations and agentic workflows in 2026?
The FreeStyle Libre 3 sensors are a bit more expensive, with two sensors priced at about $174.14 for a 28-day supply.
Prices can vary based on location and the specific retailer, with direct pharmacy purchases for two sensors often ranging from $130 to $140.
Discounts can significantly help lower costs; for example, GoodRx may reduce the monthly price of FreeStyle Libre to about $78.82.
The FreeStyle Libre systems provide continuous glucose monitoring (CGM) by using a small sensor that can be worn on the back of the upper arm for up to 14 days or 28 days, depending on the model.
The sensors utilize glucose oxidase, an enzyme that interacts with glucose in the interstitial fluid, generating an electrical signal corresponding to glucose levels.
The FreeStyle Libre 2 offers optional alarms for hypoglycemia or hyperglycemia alerts, enhancing safety for users who may not feel symptoms.
The FreeStyle Libre 3 claims to measure glucose levels every minute, providing users with real-time data that is accessible via a smartphone app.
Many insurance plans offer coverage for the FreeStyle Libre systems, which can significantly reduce out-of-pocket expenses for users.
The competitive pricing of the FreeStyle Libre system is attributed to advances in glucose monitoring technology that result in lower manufacturing costs.
Users of FreeStyle Libre systems can manage their diabetes with fewer fingersticks, as the CGM provides data without the need for frequent blood glucose testing.
The sensors are waterproof, allowing users to swim or bathe without needing to remove them.
Clinical studies suggest continuous glucose monitoring can lead to better glycemic control compared to traditional monitoring methods.
Some users report improved quality of life due to greater awareness and control over their glucose levels, reducing instances of severe hypoglycemia.
Abbott, the manufacturer of the FreeStyle Libre, has been offering patient assistance programs to help those who are uninsured or underinsured access their products.
The development of the FreeStyle Libre system is part of a broader trend in diabetes care moving towards more patient-centered, technology-driven solutions.
The effectiveness of CGM technology like FreeStyle Libre has been recognized in diabetes management guidelines, indicating its role in improving patient outcomes.
The sensors are designed to provide readings that can be shared with healthcare providers, facilitating more informed treatment decisions.
As technology advances, future iterations of glucose monitoring systems may further reduce costs, improve accuracy, or enhance patient experience.